MT-202 - Acute Ischemic Stroke, Heart Failure with preserved Ejection Fraction
MT-202, a novel bispecific Ab, for treating ischemic stroke
MT-202 simultaneously activates Tie2 and inhibits 'X'
First-in-class antibody therapy
A fully humanized antibody that, unlike conventional clotting cascade inhibitors, targets a novel regulator of thrombosis
Innovative mechanism profile
· Thrombus inhibition and resolution
· Protection against endothelial injury during ischemia/reperfusion
· Anti-inflammatory and vascular-stabilizing effects
Unmet Needs
· Stroke: ~12 million new cases annually worldwide, reperfusion injury remains a major limitation despite current therapies
· Myocardial Infarction (MI): >9 million cases annually, with post-PCI reperfusion injury a critical driver of poor outcomes
· Current therapies cannot simultaneously address thrombosis, endothelial injury, and inflammation
Commercial value & expansion
MT-202, as the first-in-class dual-mechanism therapy, delivers a differentiated approach in the multi-billion-dollar cardiovascular
and cerebrovascular markets, with potential to serve as a next-generation option across acute reperfusion, preventive, and chronic care settings